A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
← catalyst calendarNCT05608044 · readout ≤ 407 d
Sponsored by Agenus Inc. (industry) · AGEN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
234actual
Sites
65
Countries
Belgium, Brazil, France +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-11-30 | actual | When the study began enrolling |
| Primary completion | Sep 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2022-11-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Colorectal Cancer
Interventions
- Drug: Botensilimab — also filed as AGEN1181
- Drug: Balstilimab — also filed as AGEN2034
- Drug: Standard of Care
Primary outcome
what the primary-completion date above is the date OFObjective Response Rate
measured First dose through up to 2 years
Permalink · AGEN's whole pipeline · Catalyst calendar · Every registered study · What changed